Question-and-Answer Session
Operator
(Operator instructions).
We will take our first question from the side of Annabel Samimy from UBS. Please go ahead.
Annabel Samimy
Thanks for taking my call. I just want a quick question on the CRF program. You mentioned that 008 has different pharmacology from the 679. Could you give us a little more color on the pharmacology and help us understand how it might be different from the next program?
Dr. Christopher O'Brien
Sure. So as you may be aware of all the group here, the discovery group here has a worked quite a bit using some animal models particularly the ABX model that have allowed us to explore the differences in several families of compounds at the receptor and we have identified a few characteristics that seemed to be profoundly important for growths with similar binding affinities yet very different impact, and this is how compounds were selected by the collaboration to take into clinic namely pick ones that were quite different in their pharmacology and we know from GSK that in some of the early clinical work that has been done namely translational medicine studies using SNRI in small numbers of subjects that these compounds act quite differently in terms of the impact they have so, similar exposure different impact of SNRI suggest that one might be more useful for example in depression than in other. That was how that decision was made.
Tim Coughlin
And Annabel this understanding of the different chemotypes and their interactions with GPCR receptors has allowed us to carve out a unique position I believe within the CRF field and also within our GnRH program.
Dr. Christopher O'Brien
And it is the same kind of observation that we are making with this pharmacology difference that have allowed us for a follow on our GnRH program to choose molecules that have a profound endocrine suppression effect, for example that would potentially be useful in oncology and other indication.
Annabel Samimy
Just a quick remark to clarify, the 702 study is a six months study but you are first requiring a three month and you will have some DXA for scans for six months?
Dr. Christopher O'Brien
Exactly. Thank you for picking up that up. So the way these trials are designed both the 702 and the 703, their total treatment duration of six months with additional post treatment safety follow up in DEXA scan but you need six months to adequately interpret DEXA data. However, we do want a read-out on some other kinds of data that will help us enter into Phase II meeting with the FDA and we can get that in three months. So for example with efficacy data and hormone data, we can get read-out within a couple of weeks but we are using the 12-week time point to give us topline information that will help inform trial design. We will know whether the FDA’s guidance with these new clinical end points has born fruit and whether I found what I would consider to be dose permitting toxicology at the highest doses, the 250 milligrams. So we will know that at three months and we can get that us a topline read-out.
- To read the full transcript on Seeking Alpha, click here »
